MedTrace Logo

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-08-03

No results posted yet for this study

Summary

The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.

Conditions

  • Tolerability
  • Healthy
  • Elderly

Interventions

DRUG

AZD9742

Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL

DRUG

Placebo

Sterile 5% dextrose solution

Sponsors & Collaborators

Principal Investigators

  • Billings W Billings, MD · Bio-Kinetic 1816 W. Mt Vernon, Springfield, MO 65802

  • Colleen Jensen · AstraZeneca

  • Brendan Smyth · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154621 on ClinicalTrials.gov